
Therapeutic indications
Survanta is indicated for treatment of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in new born premature infants with a birth weight of 700g or greater and who are intubated and are receiving mechanical ventilation.Survanta is also indicated for the prophylactic treatment of premature infants <32 weeks gestational age at risk of developing RDS.
Key points:
Pharmacodynamic properties
Pharmacokinetic properties
Preclinical safety data
There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
Special precautions for disposal and another handling
![]() |
SALVAVIDAS PHARMACEUTICAL PVT. LTD.
All Rights Reserved.(Terms of Use) Developed and Managed by Infocom Network Private Limited. |